News & Updates

Treatment with oral roflumilast results in reduced body weight and appetite after 24 weeks in patients with psoriasis, a study has shown.

Individuals with type 1 diabetes (T1D) may engage in postprandial exercise so long as they take necessary precautions (ie, prandial insulin reductions), suggests a study.

A new tool for identifying potentially inappropriate prescribing (PIP) in people with type 2 diabetes (T2D) has been validated in the outpatient setting, according to an Ethiopian study.

Findings from the phase IV INHALE-3 trial support inhaled insulin for the management of type 1 diabetes (T1D) in adults, underlining its role as an alternative insulin solution to enhance diabetes management.

An automated insulin delivery (AID) system appears to improve clinical outcomes in people with type 2 diabetes (T2D), with the pivotal SECURE-T2D trial showing substantial improvements in glycated haemoglobin, total daily insulin dose, and diabetes distress, without increasing the risk of hypoglycaemia.

Pemvidutide, an investigational, peptide-based GLP-1/glucagon dual receptor agonist, gains traction in the booming obesity drug market, delivering significant weight loss reductions in nondiabetic individuals with overweight or obesity in the phase II MOMENTUM trial.